BeiGene Ltd. undefined said Monday it had entered an agreement with Swiss drug company Novartis Pharma AG undefined to develop its investigational TIGIT...
BeiGene Ltd.
said Monday it had entered an agreement with Swiss drug company Novartis Pharma AG NVS, -0.20% to develop its investigational TIGIT inhibitor ociperlimab in North America, Europe, and Japan and to market five Novartis oncology treatments in China."Ociperlimab is an investigational potent TIGIT inhibitor with intact Fc function, believed to be critical for the anti-tumor activities of TIGIT antibodies," the companies said in a joint statement.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Pinterest Asks Court To Dismiss Influencer’s Claim That She’s An Uncredited CofounderChristine Martinez filed a lawsuit in September, claiming the social media company’s long-acknowledged cofounders owed her a stake in the business that might be worth $1 billion or more.
Weiterlesen »
Pinterest Asks Court To Dismiss Influencer’s Claim That She’s An Uncredited CofounderChristine Martinez filed a lawsuit in September, claiming the social media company’s long-acknowledged cofounders owed her a stake in the business that might be worth $1 billion or more.
Weiterlesen »
Opinion | Educators Inspired Amid CovidFrom WSJopinion: The STOP Award’s first recipient, a Missouri museum that became a school during Covid, is another reminder that if America wants more innovators it needs more school choice.
Weiterlesen »
The Hottest Pop-Up Is at Your Local RestaurantDuring the pandemic, restaurants have relied on pop-ups to fill quiet dining rooms
Weiterlesen »
Novartis says ligelizumab suffers setback in late-stage studiesSwiss drugmaker Novartis said on Monday its ligelizumab antibody treatment against recurring hives did not meet the goal of superiority to standard treatment omalizumab in a late-stage study.
Weiterlesen »
Key US Senator delivers blow to Biden's $1.75T social spending billUS Senator Joe Manchin, a moderate Democrat who is key to President Joe Biden's hopes of passing a $1.75 trillion domestic investment bill, says he will not support the package, drawing a sharp rebuke from the White House
Weiterlesen »